Video

Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

Author(s):

Kathryn E. Beckermann, MD, PhD,Moshe Ornstein, MD, MA

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Related Videos
Chad Tang, MD
Martin H. Voss, MD
Martin H. Voss, MD
Alexandra Drakaki, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Alexandra Drakaki, MD, PhD
Adam E. Singer, MD, PhD
Chad Tang MD, MD Anderson
Alexandra Drakaki, MD, PhD
Alexandra Drakaki, MD, PhD
Related Content
Alan Tan, MD
October 18th 2024

Long-Term IO-IO Data Contest the Role of Frontline TKIs in Advanced RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Eric Jonasch, MD, physician, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 14th 2024

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Saby George, MD, FACP, Professor, Oncology and Medicine, Director, Network Clinical Trials, Roswell Park
October 1st 2024

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

RCC: stock.adobe.com
October 1st 2024

Fecal Microbiota Transplantation Boosts Response to Pembrolizumab Plus Axitinib in mRCC